Sari la conținut

Aclaris Therapeutics Inc: Diferență între versiuni

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
(Pagină nouă: Pagina dedicata companiei Aclaris Therapeutics Inc listata cu simbolul US.ACRS ==Descriere companie== Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein...)
 
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).)
 
Linia 2: Linia 2:


==Descriere companie==
==Descriere companie==
Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.
Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include [[ATI]]-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.


==Grafic actiuni companie==
==Grafic actiuni companie==
Utilizator anonim